CELMoDs and T-Cell Fitness in Multiple Myeloma: Immune Effects and Implications for T-Cell-Redirecting Therapies

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith introduce cereblon E3 ligase modulators (CELMoDs) and discuss their dual activity in multiple myeloma.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.